IRIS Catalogo Istituzionale della Ricerca dell'Università degli Studi del Molise
IRIS è il Catalogo Istituzionale della Ricerca dell'Università degli Studi del Molise ed ha lo scopo di consentire la conservazione e la consultazione delle informazioni sulla produzione scientifica dell'Ateneo.
EnglishEvaluation of: Kavanaugh A, Ritchlin C, Rahman P et al.; on behalf of the PSUMMIT-1 and -2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the Phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann. Rheum. Dis. 73(6), 1000–1006 (2014). The IL-23/IL-17 axis plays a major role in the immunopathogenesis of psoriatic arthritis (PsA), inducing the production of proinflammatory cytokines (e.g., IL-1, TNF-α, IL-6 and IL8), osteoclastogenesis and cartilage degradation. This pathway represents a novel target in the treatment of PsA. Ustekinumab is a human monoclonal antibody that prevents the human IL-12/IL-23 p40 subunit from binding to the IL12Rβ1 receptor chain. The current paper sustains that clinical efficacy of ustekinumab is associated with inhibition of radiological progression in active PsA.
| Digital Object Identifier (DOI): | http://dx.doi.org/10.2217/IMT.14.39 |
| Codice identificativo ISI: | WOS:000337220000008 |
| Codice identificativo Scopus: | 2-s2.0-84902118934 |
| Handle: | http://hdl.handle.net/11695/2145 |
| URL: | http://www.ncbi.nlm.nih.gov/pubmed/24896622 |
| Titolo: | A novel biological target for the treatment of psoriatic arthritis. |
| Autori: | |
| Appare nelle tipologie: | 1.1 Articolo in rivista |
File in questo prodotto:
Copyright © 2020